Supernus Pharmaceuticals Inc (NASDAQ:SUPN) got downgraded

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) received a stock rating downgrade from Piper Jaffray on Jul-18-16. In a note to investors, the firm issued a Neutral rating. The analysts previously had an Overweight rating on the stock. The 52-week price range is $9.51-$23.30 and the company has a market capitalization of $1.03 billion. Analysts covering the shares … Continue reading “Supernus Pharmaceuticals Inc (NASDAQ:SUPN) got downgraded”